Middle East & Africa Drug Discovery Informatics Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Middle East and Africa Drug Discovery Informatics Market size is expected to reach US$ 273.7 Million by 2031 from US$ 144.0 Million in 2024. The market is estimated to record a CAGR of 9.9% from 2025 to 2031.

Executive Summary and Middle East and Africa Drug Discovery Informatics Market Analysis:

The Middle East and Africa shows promising but uneven growth in drug discovery informatics, with progress concentrated in Gulf Cooperation Council countries. Saudi Arabia's National Transformation Program has directed $1.5 billion toward healthcare AI development since 2021, including the establishment of the King Abdullah University of Science and Technology's bioinformatics center. The UAE reports that 60% of its pharmaceutical manufacturers now utilize some form of predictive analytics, supported by the Dubai Health Authority's cloud computing infrastructure. South Africa's Department of Science and Innovation invested ZAR 450 million in digital health initiatives in 2023. However, sub-Saharan Africa collectively spends less than 0.5% of its GDP on pharmaceutical research and development. Israel emerges as an outlier, with its Office of the Chief Scientist funding over 50 AI-based drug discovery startups. The region faces significant data standardization and infrastructure challenges, but strategic partnerships with global pharmaceutical companies and specialized initiatives such as Qatar's precision medicine program demonstrate growing potential.

Middle East & Africa Drug Discovery Informatics Market: Strategic Insights

Middle East and Africa Drug Discovery Informatics Market Segmentation Analysis:

• By Workflow, the Middle East and Africa Drug Discovery Informatics Market is segmented into Discovery Informatics and Drug Development. The Discovery Informatics segment dominated the market in 2024.
• By Service, the Middle East and Africa Drug Discovery Informatics Market is segmented into Sequence Analysis Platform, Molecular Modelling, Clinical Trial Data Management, Docking, and Others. The Sequence Analysis Platform segment dominated the market in 2024.
• By Solutions, the Middle East and Africa Drug Discovery Informatics Market is segmented into Software and Services. The Software segment dominated the market in 2024.
• By End User, the Middle East and Africa Drug Discovery Informatics Market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), and Others. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

Middle East & Africa Drug Discovery Informatics Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Drug Discovery Informatics Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East and Africa Drug Discovery Informatics Market Outlook

The integration of artificial intelligence (AI) and machine learning (ML) into drug discovery informatics is one of the most transformative trends shaping the pharmaceutical industry today. These technologies enable unprecedented data processing capabilities, allowing researchers to analyze complex biological, chemical, and clinical datasets at scale. AI and ML algorithms can identify hidden patterns, predict molecular interactions, and optimize compound screening, significantly accelerating drug discovery.

By automating repetitive tasks such as data cleaning, feature selection, and molecular docking, AI-powered platforms free up valuable human resources to focus on strategic scientific inquiry and decision-making. Moreover, predictive analytics models improve the accuracy of candidate selection, reducing costly late-stage failures that historically plague drug development pipelines.

Pharmaceutical companies investing in AI/ML technologies are gaining a competitive advantage through shorter discovery timelines and enhanced precision in targeting disease pathways. This leads to more effective drug candidates and personalized treatment options aligned with patient-specific biological profiles. AI's ability to rapidly integrate and interpret multi-omics data further enhances the discovery of novel biomarkers and therapeutic targets.

Middle East and Africa Drug Discovery Informatics Market Country Insights

By country, the Middle East and Africa Drug Discovery Informatics Market is segmented into Saudi Arabia, South Africa, the United Arab Emirates, and the Rest of Middle East and Africa. Saudi Arabia held the largest share in 2024.

The Saudi Arabia drug discovery informatics market is experiencing strong growth as part of the country's ambitious "Vision 2030" plan to diversify its economy and enhance its healthcare sector. The government is making significant investments in research and development, with spending on research and development rising to SAR 19.2 billion in 2022. This push for innovation is creating a need for advanced informatics tools to support the development of a domestic pharmaceutical industry. While the country has historically relied on imported drugs, there is a strong focus on increasing local production, with a goal of producing 40% of all drugs domestically. This shift is a major catalyst for the adoption of informatics solutions to streamline research and development, manage clinical trials, and optimize manufacturing processes.

Middle East and Africa Drug Discovery Informatics Market Company Profiles

Some of the key players operating in the market include Dassault Systèmes SE, Eurofins Scientific SE, Charles River Laboratories International Inc, Jubilant Pharma Limited, Revvity Inc, Thermo Fisher Scientific Inc., Certera, Selvita, Collaborative Drug Discovery, Inc., and Illumina, Inc

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East and Africa Drug Discovery Informatics Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise